Hanall Biopharma Co., Ltd. (009420.KS) KSC

Currency In KRW

AD

Valuation

Market Cap2.18T
Enterprise Value2.19T
P/E Ratio-103.92
PEG Ratio-0.16
Price/Sales Ratio15.66
Price/Book Ratio16.19
Enterprise/Revenue15.76
Enterprise/EBITDA-189.28

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.15
Operating Margin0.02
AD

Management Effectiveness

Return On Assets-0.1
Return On Equity-0.15

Income Statement

Revenue155.18B
Revenue/Share3,113.64
Gross Profit79.1B
EBITDA1.94B
Net Income-5.56B
Diluted EPS-111.55

Balance Sheet

Total Cash30.2B
Total Cash/Share578.01
Total Debt44.99B
Total Debt/Equity0.28
Current Ratio1.49
Book Value Per Share3,093.85

Price History

52-Week Change50
52-Week High73,000
52-Week Low30,400
Moving Average 50 Days54,744
Moving Average 200 Days52,235

Statistics

Average Volume430,098
Shares Outstanding50.86M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor10:1
Last Split DateMay 03, 2006
AD